Role of CD24 in Anoikis Resistance of Ovarian Cancer Cells

• Published in: Journal of Huazhong University of Science and Technology. Medical sciences Vol. 35; no. 3; pp. 390 - 396
• Main Author: 李艳辉 孙翔 汪宏波
• Format: Journal Article
• Language: English
• Published: Wuhan Huazhong University of Science and Technology 01.06.2015; Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
• Subjects: Anoikis; CD24 Antigen - genetics; CD24 Antigen - metabolism; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Female; Humans; Medicine; Medicine & Public Health; Ovarian Neoplasms - genetics; Ovarian Neoplasms - metabolism; RT-PCR; 卵巢癌细胞; 悬浮培养; 比色分析法; 流式细胞仪; 细胞凋亡; 蛋白表达; 贴壁培养; CD24; ovarian cancer; metastasis; anoikis resistance
• ISSN: 1672-0733; 1993-1352
• DOI: 10.1007/s11596-015-1443-0

This study examined the effect of CD24 on anoikis of ovarian cancer cells. The expres- sion of CD24 was detected by RT-PCR and Western blotting in ovarian cancer cells with high metas- tatic potential （HO-8910PM cells） and low metastatic potential （A2780 cells）. Cell viability and cell proliferation were detected by MTT assay in suspension culture and adhesion culture. Soft agar cul- ture was used to observe the colony formation. Anoikis was flow cytometrically detected. The results showed that the expression levels of CD24 mRNA and protein were significantly higher in HO-8910PM cells than in A2780 cells （P〈0.01）. In the suspension culture and soft agar culture, the HO-8910PM cells formed larger and more colonies （35.334-5.51 vs. 16.674-4.04; P〈0.01）, and showed a stronger resistance to anoikis than A2780 cells did （cell apoptosis rate： 5.93%4-2.38% vs. 16.32%-4-2.00%; P〈0.01）. After treated with CD24 monoclonal antibodies, the number of colony formed in HO-8910PM and A2780 cells was significantly decreased （9.334-2.52 and 8.004-2.00, re- spectively）, and the anoikis rate of the two cell lines was also markedly increased （23.11%4-2.87% and 28.36%~2.29%, respectively）. Our study suggested that CD24 may play an important role in the development of anoikis resistance and CD24 can be used as a new therapeutic target to induce anoikis and inhibit metastasis in ovarian cancer.